Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin

Ann Clin Microbiol Antimicrob. 2009 Apr 15:8:12. doi: 10.1186/1476-0711-8-12.

Abstract

Intravesical administration of Bacillus Calmette-Guérin is used as a treatment method in superficial bladder cancer. While it is generally well tolerated, serious side effects may develop. Granulomatous hepatitis cases have been previously reported; however, only one case with tuberculous peritonitis exists in the current literature. We hereby present two cases, one of which is the second tubercular peritonitis case following Bacillus Calmette-Guérin treatment to be reported, and the other a case with granulomatous hepatitis. Complete cure was achieved in both cases with specific therapy. In the patient who developed peritonitis, intravesical Bacillus Calmette-Guérin therapy was recommenced after antituberculosis treatment, and completed without further complications.

Publication types

  • Case Reports

MeSH terms

  • Administration, Intravesical
  • Adult
  • Antitubercular Agents / therapeutic use
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / adverse effects*
  • BCG Vaccine / therapeutic use
  • Female
  • Granuloma / drug therapy
  • Granuloma / etiology*
  • Hepatitis / drug therapy
  • Hepatitis / etiology*
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium bovis / immunology
  • Peritonitis, Tuberculous / drug therapy
  • Peritonitis, Tuberculous / etiology*
  • Treatment Outcome
  • Urinary Bladder Neoplasms / immunology
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Antitubercular Agents
  • BCG Vaccine